Where is Allovate located?

Allovate is headquartered in New York City, United States.

How many employees does Allovate have?

As of Jul 31, 2026, the latest employee count at Allovate is 4.

Where does Allovate rank among its competitors?

Allovate ranks 142nd amongst 194 active competitors, of which 60 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Mabylon, which secured $37M in Aug, 2025.

Who are the top competitors of Allovate?

Allovate's top competitors include BeiGene, BioNTech and DBV Technologies. Among them, Mabylon secured the most recent funding round in August, 2025.

Allovate - 2026 Company Profile, Team & Competitors

Company Details

Simplifying allergen delivery through customized toothpaste for healthcare providers and patients. This innovative platform offers a unique approach to allergy immunotherapy by incorporating allergens into a proprietary toothpaste base. Physicians and pharmacists can compound patient-specific formulations, delivered through daily tooth brushing. This eliminates the need for extra steps or invasive procedures, making it convenient for both children and adults. The platform streamlines allergy management, offering a simple and effective solution for patients suffering from nasal congestion, sneezing, and other allergy symptoms. It is a B2B and B2C healthcare solution that simplifies the process of allergy desensitization. The website offers features like sign in, my account, cart, and stay in touch options.

Website: allovate.com
Social

Key Metrics

Founded Year

2012

Location

New York City, United States

Stage

Unfunded

Ranked

142^nd among 194 active competitors

Employee Count

4 as on Jul 31, 2026

Similar Companies

BeiGene & 239 more

View Allovate's full profile

Allovate has not raised any funding rounds yet.

The founders of Allovate are Michael Nelson and Erick Berglund.

Here are the details of Allovate's key team members:

Michael Nelson: Former Co-Founder of Allovate and founder of 2 other companies, Intrommune and Immunovent.
Contact Info: 3 email addresses
Erick Berglund: Former Co-Founder & CEO of Allovate.
Contact Info: 1 email address

View details of Allovate's Founder profiles and Board Members

Allovate's employee count trend

Allovate has 4 employees as of Jul 26. Here is Allovate's employee count trend over the years:

Uncover Allovate's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Allovate include BeiGene, BioNTech and DBV Technologies. Here is the list of Top 10 competitors of Allovate, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
3rd	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
4th	IgGenix 2019, San Francisco (United States), Series B	Developer of therapeutic solutions for treating food allergy	$75M	Khosla Ventures, Alexandria & 7 others	63/100
5th	Serum Institute of India 1966, Pune (India), Funding Raised	Manufacturer of vaccines and immuno-biological drugs for infectious diseases	-	Fortune Intercontinental, Cyrus Poonawalla Family Trust ... & 9 others	62/100
6th	Stallergenes Greer 2013, London (United Kingdom), Acquired	Developing allergen immunotherapy (vaccine) for respiratory allergies	-	Waypoint Capital, B-FLEXION	62/100
7th	Immunomic Therapeutics 2005, Rockville (United States), Series B	Vaccines for allergy, cancer and infectious disease.	$104M	HLB, Defense.gov & 7 others	62/100
8th	AC Immune 2003, Lausanne (Switzerland), Public	Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative diseases	$120M	BVF Partners, Redmile Group & 4 others	61/100
9th	Mabylon 2015, Schlieren (Switzerland), Series B	Developer of therapeutics for allergies and neurodegenerative diseases	$37M	Admin, EIC Fund & 3 others	60/100
10th	RAPT 2015, San Francisco (United States), Acquired	Provider of immunology-based drug for oncology and inflammatory diseases	$199M	The Column Group, Celgene & 19 others	59/100
142nd	Allovate 2012, New York City (United States), Unfunded	Simplifying allergen delivery through customized toothpaste for healthcare providers and patients	-	-	26/100